Top Companies Innovating in GLP-1 Obesity Treatments in 2025

Key Companies Innovating in GLP-1 Obesity Treatments

In 2025, the landscape of obesity treatment is being reshaped by innovative companies developing GLP-1 (glucagon-like peptide-1) receptor agonists. These therapies, initially designed for type 2 diabetes, have demonstrated significant weight loss benefits, leading to their expanded use in obesity management.

1. Eli Lilly

Role & Responsibilities:

• Eli Lilly is a leader in developing GLP-1 therapies, including tirzepatide (Zepbound) and the oral GLP-1 drug orforglipron.

Recent Developments:

• Initiated Phase 3 trials for orforglipron, aiming to provide an oral alternative to injectable GLP-1 drugs.
• Announced plans to build a $6.5 billion manufacturing facility in Houston, Texas, to support the production of orforglipron and other medications.

2. Novo Nordisk

Role & Responsibilities:

• Novo Nordisk has been at the forefront with its GLP-1 drugs, such as semaglutide (Wegovy), demonstrating substantial weight loss efficacy.

Recent Developments:

• Continued expansion of Wegovy's indications, including applications for cardiovascular risk reduction. 
• Presented data on combination therapies at the 2025 ADA meeting, exploring synergistic effects with other metabolic agents.

3. Pfizer

Role & Responsibilities:

• Pfizer has entered the obesity treatment arena through strategic acquisitions.

Recent Developments:

• Acquired Metsera Inc. for $4.9 billion, gaining access to Metsera's promising GLP-1 pipeline, including oral and injectable formulations.

4. Amgen

Role & Responsibilities:

• Amgen is developing dual GLP-1/GIP receptor agonists, aiming to enhance weight loss and metabolic control.

Recent Developments:

• Initiated Phase 3 trials for maritide (caftaglutide), targeting both GLP-1 and GIP receptors.

5. Hanmi Pharmaceutical

Role & Responsibilities:

• Hanmi is advancing multi-receptor agonists to address obesity and related metabolic conditions.

Recent Developments:

• Developed HM15275, a tri-agonist targeting GLP-1, GIP, and glucagon receptors, showing potential for significant weight loss and improved metabolic health.

Market Growth

The global GLP-1 drugs market size was US$ 48.3 billion in 2024 and is forecast to increase to US$ 52.95 billion by 2025. By the end of 2034, it is expected to grow US$ 121.13 billion, growing steadily at a CAGR of 9.63%.

Challenges in the GLP-1 Obesity Treatment Landscape

• Access and Affordability: High costs of GLP-1 drugs limit accessibility for many patients.
• Side Effects and Efficacy Variability: Patients may experience gastrointestinal side effects, and real-world efficacy can vary compared to clinical trial results. 
• Regulatory and Market Dynamics: Regulatory approvals and market competition influence the availability and pricing of these therapies. 

Solutions and Innovations

• Development of Oral Formulations: Companies like Eli Lilly are focusing on oral GLP-1 drugs to improve patient adherence and convenience.
• Combination Therapies: Exploring combinations with other metabolic agents to enhance efficacy and address multiple aspects of obesity.
• Global Expansion: Increasing availability in diverse markets to reach a broader patient population.

Recent Updates

• Eli Lilly's Strategic Expansion: Eli Lilly's $6.5 billion investment in a new manufacturing facility underscores its commitment to scaling production of GLP-1 therapies.
• Pfizer's Acquisition of Metsera: Pfizer's acquisition of Metsera Inc. positions it to compete in the evolving obesity treatment market with innovative GLP-1 therapies.
• Advancements in Combination Therapies: Presentations at the 2025 ADA meeting highlighted the potential of combining GLP-1 drugs with other metabolic agents to enhance treatment outcomes.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com